These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 25128112)

  • 21. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis.
    Gottlieb AB; Chaudhari U; Mulcahy LD; Li S; Dooley LT; Baker DG
    J Am Acad Dermatol; 2003 Jun; 48(6):829-35. PubMed ID: 12789171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Life-threatening pustular and erythrodermic psoriasis responding to infliximab.
    Lewis TG; Tuchinda C; Lim HW; Wong HK
    J Drugs Dermatol; 2006 Jun; 5(6):546-8. PubMed ID: 16774108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of pustular psoriasis with infliximab.
    Weishaupt C; Metze D; Luger TA; Ständer S
    J Dtsch Dermatol Ges; 2007 May; 5(5):397-9. PubMed ID: 17451384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [News on psoriasis from the 2010 Dermatology Days in Paris].
    Boulinguez S
    Ann Dermatol Venereol; 2011 May; 138(5 Suppl 1):H1-5. PubMed ID: 21703458
    [No Abstract]   [Full Text] [Related]  

  • 25. [Efficacy of treatment with infliximab in patients with moderate-severe psoriasis and high needs of therapy. A retrospective study of 43 patients].
    Puig L
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():30-5. PubMed ID: 19080989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Infliximab].
    Herrera E; Habicheyn S
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():7-13. PubMed ID: 19080986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.
    Reich K; Nestle FO; Papp K; Ortonne JP; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE;
    Lancet; 2005 Oct 15-21; 366(9494):1367-74. PubMed ID: 16226614
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Central retinal vein occlusion following infliximab treatment for plaque-type psoriasis.
    Vergou T; Moustou AE; Maniateas A; Stratigos AJ; Katsambas A; Antoniou C
    Int J Dermatol; 2010 Oct; 49(10):1215-7. PubMed ID: 20883414
    [No Abstract]   [Full Text] [Related]  

  • 29. Infliximab: efficacy in psoriasis.
    Arsiwala S
    Indian J Dermatol Venereol Leprol; 2013 Jul; 79 Suppl 7():S25-34. PubMed ID: 23974692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
    Barker J; Hoffmann M; Wozel G; Ortonne JP; Zheng H; van Hoogstraten H; Reich K
    Br J Dermatol; 2011 Nov; 165(5):1109-17. PubMed ID: 21910713
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of infliximab for severe recalcitrant psoriasis after 6 weeks of treatment.
    DE Oliveira JP; Levy A; Morel P; Guibal F
    J Dermatol; 2008 Sep; 35(9):575-80. PubMed ID: 18837702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tremfya™ (Guselkumab).
    Abramovits W; Wiqas A; Vincent KD; Versteeg SG; Gupta AK
    Skinmed; 2019; 17(1):36-38. PubMed ID: 30888946
    [No Abstract]   [Full Text] [Related]  

  • 33. Practical understanding of mean percent psoriasis area and severity index reduction for biologics.
    English PL; Vender R
    J Cutan Med Surg; 2008; 12(6):282-7. PubMed ID: 19317950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discussion about alopecia areata emergence as a class-dependent effect of anti-TNFα.
    Duarte GV
    An Bras Dermatol; 2012; 87(2):338. PubMed ID: 22570053
    [No Abstract]   [Full Text] [Related]  

  • 35. Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody.
    Tan MH; Gordon M; Lebwohl O; George J; Lebwohl MG
    Arch Dermatol; 2001 Jul; 137(7):930-3. PubMed ID: 11453813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efalizumab. Long-term treatment of psoriasis].
    Prinz JC
    Hautarzt; 2005 Sep; 56(9):812-8. PubMed ID: 16096737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infliximab in psoriasis and psoriatic arthritis.
    Papoutsaki M; Osório F; Morais P; Torres T; Magina S; Chimenti S; Costanzo A
    BioDrugs; 2013 Jan; 27 Suppl 1():13-23. PubMed ID: 23990278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term efficacy and safety of infliximab maintenance therapy in patients with plaque-type psoriasis in real-world practice.
    Shear NH; Hartmann M; Toledo-Bahena M; Katsambas A; Connors L; Chang Q; Yao R; Nograles K; Popmihajlov Z;
    Br J Dermatol; 2014 Sep; 171(3):631-41. PubMed ID: 24673357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review.
    Kamili QU; Miner A; Hapa A; Menter A
    J Drugs Dermatol; 2011 May; 10(5):539-44. PubMed ID: 21533302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treating psoriasis patients with biologic agents.
    Pariser DM
    Manag Care; 2003 Dec; 12(12):50-7; discussion 57-9; quiz 60-2. PubMed ID: 14723104
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.